Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
1371 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2016', provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - The report reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics and enlists all their major and minor projects - The report assesses Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 10 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Overview 11 Therapeutics Development 12 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Development by Companies 14 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 31 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Products Glance 34 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Development by Companies 38 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Products under Investigation by Universities/Institutes 68 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 72 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 272 Drug Profiles 325 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1293 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1311 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1317 Appendix 1327
List of Tables
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H1 2016 54 Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Comparative Analysis, H1 2016 55 Number of Products under Development by Companies, H1 2016 57 Number of Products under Development by Companies, H1 2016 (Contd..1) 58 Number of Products under Development by Companies, H1 2016 (Contd..2) 59 Number of Products under Development by Companies, H1 2016 (Contd..3) 60 Number of Products under Development by Companies, H1 2016 (Contd..4) 61 Number of Products under Development by Companies, H1 2016 (Contd..5) 62 Number of Products under Development by Companies, H1 2016 (Contd..6) 63 Number of Products under Development by Companies, H1 2016 (Contd..7) 64 Number of Products under Development by Companies, H1 2016 (Contd..8) 65 Number of Products under Development by Companies, H1 2016 (Contd..9) 66 Number of Products under Development by Companies, H1 2016 (Contd..10) 67 Number of Products under Development by Companies, H1 2016 (Contd..11) 68 Number of Products under Development by Companies, H1 2016 (Contd..12) 69 Number of Products under Development by Companies, H1 2016 (Contd..13) 70 Number of Products under Development by Companies, H1 2016 (Contd..14) 71 Number of Products under Development by Companies, H1 2016 (Contd..15) 72 Number of Products under Investigation by Universities/Institutes, H1 2016 73 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 74 Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 75 Comparative Analysis by Late Stage Development, H1 2016 76 Comparative Analysis by Clinical Stage Development, H1 2016 77 Comparative Analysis by Early Stage Development, H1 2016 78 Comparative Analysis by Unknown Stage Development, H1 2016 79 Products under Development by Companies, H1 2016 80 Products under Development by Companies, H1 2016 (Contd..1) 81 Products under Development by Companies, H1 2016 (Contd..2) 82 Products under Development by Companies, H1 2016 (Contd..3) 83 Products under Development by Companies, H1 2016 (Contd..4) 84 Products under Development by Companies, H1 2016 (Contd..5) 85 Products under Development by Companies, H1 2016 (Contd..6) 86 Products under Development by Companies, H1 2016 (Contd..7) 87 Products under Development by Companies, H1 2016 (Contd..8) 88 Products under Development by Companies, H1 2016 (Contd..9) 89 Products under Development by Companies, H1 2016 (Contd..10) 90 Products under Development by Companies, H1 2016 (Contd..11) 91 Products under Development by Companies, H1 2016 (Contd..12) 92 Products under Development by Companies, H1 2016 (Contd..13) 93 Products under Development by Companies, H1 2016 (Contd..14) 94 Products under Development by Companies, H1 2016 (Contd..15) 95 Products under Development by Companies, H1 2016 (Contd..16) 96 Products under Development by Companies, H1 2016 (Contd..17) 97 Products under Development by Companies, H1 2016 (Contd..18) 98 Products under Development by Companies, H1 2016 (Contd..19) 99 Products under Development by Companies, H1 2016 (Contd..20) 100 Products under Development by Companies, H1 2016 (Contd..21) 101 Products under Development by Companies, H1 2016 (Contd..22) 102 Products under Development by Companies, H1 2016 (Contd..23) 103 Products under Development by Companies, H1 2016 (Contd..24) 104 Products under Development by Companies, H1 2016 (Contd..25) 105 Products under Development by Companies, H1 2016 (Contd..26) 106 Products under Development by Companies, H1 2016 (Contd..27) 107 Products under Development by Companies, H1 2016 (Contd..28) 108 Products under Development by Companies, H1 2016 (Contd..29) 109 Products under Investigation by Universities/Institutes, H1 2016 110 Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 111 Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 112 Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 113 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H1 2016 114 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H1 2016 115 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc., H1 2016 116 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 117 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 118 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H1 2016 119 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories, LLC, H1 2016 120 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016 121 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H1 2016 122 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals, Inc., H1 2016 123 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics B.V., H1 2016 124 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Akinion Pharmaceuticals AB, H1 2016 125 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Altor BioScience Corporation, H1 2016 126 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc., H1 2016 127 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antigen Express, Inc., H1 2016 128 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Limited, H1 2016 129 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H1 2016 130 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea AB, H1 2016 131 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by arGEN-X BV, H1 2016 132 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 133 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arno Therapeutics, Inc., H1 2016 134 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals, Inc., H1 2016 135 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Array BioPharma Inc., H1 2016 136 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc., H1 2016 137 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 138 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals, Inc., H1 2016 139 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H1 2016 140 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics, Inc., H1 2016 141 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex, Inc., H1 2016 142 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 143 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 144 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H1 2016 145 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma, H1 2016 146 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 147 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BerGenBio AS, H1 2016 148 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 149 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2016 150 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioInvent International AB, H1 2016 151 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioLineRx, Ltd., H1 2016 152 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BioSight Ltd., H1 2016 153 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Blueprint Medicines Corporation, H1 2016 154 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 155 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Boston Biomedical, Inc., H1 2016 156 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2016 157 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Calithera Biosciences, Inc., H1 2016 158 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2016 159 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantargia AB, H1 2016 160 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 161 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cascadian Therapeutics Inc, H1 2016 162 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H1 2016 163 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celgene Corporation, H1 2016 164 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellceutix Corporation, H1 2016 165 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celldex Therapeutics, Inc., H1 2016 166 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellectis S.A., H1 2016 167 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cellerant Therapeutics, Inc., H1 2016 168 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Celyad SA, H1 2016 169 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CharlestonPharma LLC, H1 2016 170 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 171 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ConverGene, LLC, H1 2016 172 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 173 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Critical Outcome Technologies Inc., H1 2016 174 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CrystalGenomics, Inc., H1 2016 175 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by CTI BioPharma Corp., H1 2016 176 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 177 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 178 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DC Prime B.V., H1 2016 179 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Debiopharm International SA , H1 2016 180 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 181 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by DiNonA Inc., H1 2016 182 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eisai Co., Ltd., H1 2016 183 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eli Lilly and Company, H1 2016 184 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EntreChem, S.L., H1 2016 185 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by EpiZyme, Inc., H1 2016 186 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Erytech Pharma SA, H1 2016 187 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016 188 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H1 2016 189 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Exelixis, Inc., H1 2016 190 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 191 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fate Therapeutics, Inc., H1 2016 192 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by FORMA Therapeutics, Inc., H1 2016 193 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H1 2016 194 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fortress Biotech, Inc., H1 2016 195 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Forty Seven Inc., H1 2016 196 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Fujifilm Corporation, H1 2016 197 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gadeta B.V., H1 2016 198 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Galen Limited, H1 2016 199 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gamida Cell Ltd., H1 2016 200 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genentech, Inc., H1 2016 201 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genoscience Pharma, H1 2016 202 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genosco, H1 2016 203 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Genzyme Corporation, H1 2016 204 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Gilead Sciences, Inc., H1 2016 205 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2016 206 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by GlycoMimetics, Inc., H1 2016 207 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Golden Biotechnology Corp., H1 2016 208 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by H3 Biomedicine Inc., H1 2016 209 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 210 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by HEC Pharm Co., Ltd., H1 2016 211 Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Huperion Sarl, H1 2016 212
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
